Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rosiglitazone in LADA and Type 2 Diabetes
ChiCTR-TRC-08000117Phase 4Completed
- Sponsor
- Diabetes Center of Central South University
- Start
- Jun 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of rosiglitazone in latent autoimmune diabetes in adults (LADA) and type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Diabetes Center of Central South University. Primary endpoints: Hemoglobin A1c (HbA1c), Beta-cell function and 3 more. Started Jun 2006; status: completed.
02
Drugs
rosiglitazone
03
Conditions
latent autoimmune diabetes in adults (LADA)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR-TRC-08000117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-08000117.